StockSelector.com
  Research, Select, & Monitor Friday, February 21, 2020 1:13:22 PM ET  
Trade Ideas The Market Industries Stocks Portfolio

 
Ticker Lookup
Ligand Pharmaceuticals, Inc.$100.53($.82)(.81%)

  Quote | Chart | Valuations | Sentiment | Industry | News | Earnings | Analysts | More...

Your Target?

Ligand Pharmaceuticals, Inc. has an overall rank of 161 out of 6036 stocks based on 13 positive rankings and 7 negative rankings.

Positive Rankings
Highest Net Margin
Ligand Pharmaceuticals rank is 5
Highest ROA
Ligand Pharmaceuticals rank is 8
Highest ROE
Ligand Pharmaceuticals rank is 26
Highest Cash Growth
Ligand Pharmaceuticals rank is 49
Estimated EPS Growth
Ligand Pharmaceuticals rank is 181
Target Prices
The average analysts' target price is $135.00 for Ligand Pharmaceuticals using target prices set or adjusted within the past 90 days. Among companies with recent target prices and with the average above the current stock price, Ligand Pharmaceuticals is ranked 255.
Estimated Revenue Growth
Ligand Pharmaceuticals rank is 304
Historic EPS Growth
Ligand Pharmaceuticals rank is 385
Historic Revenue Growth
Ligand Pharmaceuticals rank is 481
10 Day Gain
Ligand Pharmaceuticals rank is 581
Debt-to-Equity
Ligand Pharmaceuticals rank is 658
SSValue
The StockSelector Value for Ligand Pharmaceuticals is $116.71. The StockSelector Value assumes the market consistently prices a stock around a given PE ratio and, therefore, multiplies the average PE (using forward earnings estimates) over the past three years by future earnings estimates. Among companies with a StockSelector Value above the current stock price, Ligand Pharmaceuticals is ranked 1084.
Up EPS Surprise
Ligand Pharmaceuticals beat the consensus earnings estimate when it last reported quarterly earnings.
Negative Rankings
High Put/Call
Ligand Pharmaceuticals has a high Put/Call ratio of 7.20 on all open interest of options expiring in the next 90 days. A high put-to-call ratio indicates there are more bearish investors than bullish investors for the stock. Among companies with a high Put/Call Ratio, Ligand Pharmaceuticals is ranked 46.
Price-to-Sales
Ligand Pharmaceuticals rank is 94
Negative Guidance
Within the past 90 days Ligand Pharmaceuticals has provided guidance belwo the consensus estimates. Statistics show companies that provide negative guidance underperform the market in the short-term.
Price-to-Book
Ligand Pharmaceuticals rank is 806
High vPut/Call
Ligand Pharmaceuticals has a high Put/Call ratio of 1.36 on active options expiring within the next 90 days. A high put-to-call ratio indicates there are more bearish investors than bullish investors for the stock. Among companies with a high Put/Call Ratio, Ligand Pharmaceuticals is ranked 891.
Overbought Stochastics
Ligand Pharmaceuticals rank is 934
90 Day Loss
Ligand Pharmaceuticals rank is 1394







Register |  Password |  Feedback |  Copyright |  Usage Agreement |  Privacy Policy |  Advertising |  About Us |  Contact Us |  FAQ 

Past performance is not indicative of future results

StockSelector.com, the StockSelector.com logo, and News Selects are trademarks of StockSelector.com.
Copyright © 1998 - 2020 StockSelector.com. All rights reserved.